# Tirzepatide Long-Term Side Effects: Where the Evidence Stops

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-14 | Updated: 2026-11-07

Canonical page: https://glpwatchdog.org/research/tirzepatide-long-term-side-effects

> The longest published randomized tirzepatide treatment in obesity is 176 weeks, and the cardiovascular trial ran a median of 46.9 months. This separates what the approved label warns about from what a trial counted, and says where the record ends.

## Key points

- 176 weeks is the longest published randomized tirzepatide treatment period in obesity, and that report covers the prediabetes subgroup of one trial.
- SURPASS-CVOT followed 13,299 adults who had both type 2 diabetes and established atherosclerotic disease for a median of 46.9 months on treatment. The result against dulaglutide was noninferiority, not superiority.
- Acute pancreatitis carries a full labeled warning, yet its adjudicated rate was 0.2% on tirzepatide against 0.2% on placebo in the pooled weight trials.
- The boxed thyroid C-cell warning rests on a two-year rat study; the label states the human relevance has not been determined, and calls routine calcitonin or ultrasound screening of uncertain value.
- The DXA substudy put the loss at roughly three-quarters fat to one-quarter lean, and the placebo arm split the same way. SURMOUNT-MMO does not read out until October 2027.

The longest published randomized experience with tirzepatide in obesity is 176 weeks (a little under three and a half years), and that figure comes from one subgroup of one trial.[4] In type 2 diabetes there is a cardiovascular outcome trial with a median of 46.9 months of treatment.[7] Past those horizons there are no data, only opinions. So the useful version of “long-term side effects” is two separate questions: what the approved label warns about, and how much of that warning is backed by a counted number.

> **This page is a description of evidence, not medical advice.** If you have a symptom, it belongs with the prescriber who manages your treatment, today rather than after more reading. Nothing here is a reason to change, hold or stop a dose on your own.

## How far the record reaches

Tirzepatide is not an old drug. FDA cleared the molecule first for type 2 diabetes, under the name Mounjaro, on May 13, 2022, and then for weight reduction, as Zepbound, on November 8, 2023.[9][10] Everything anyone knows about taking it for years comes from a small number of trials that were designed to end. The same is true across the class, as our list of [the longest GLP-1 studies](https://glpwatchdog.org/research/lists/top-glp1-long-term-safety-studies) shows. This page is about how far that *evidence* reaches; for how long an individual symptom tends to last, see [how long GLP-1 side effects last](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last).

*Where the randomized tirzepatide evidence stops. Durations as reported by each trial.*

| Trial | Population | How long | What it was built to answer |
| --- | --- | --- | --- |
| SURMOUNT-1, primary report | 2,539 adults with obesity or overweight, no diabetes | 72 weeks, including a 20-week escalation period | Weight change and tolerability.[3] |
| SURMOUNT-1, 3-year report | The 1,032 of those participants who also had prediabetes | 176 weeks on assigned treatment, then 17 weeks off it | Whether progression to type 2 diabetes was delayed, plus 3-year safety.[4] |
| SURMOUNT-4 | 670 adults randomized after an open-label run-in | 36-week lead-in, then 52 weeks blinded — 88 weeks total | What happens to weight when the drug is withdrawn.[5] |
| SURPASS-CVOT | 13,299 adults who had both type 2 diabetes and established atherosclerotic disease | Median treatment duration 46.9 months | Whether tirzepatide was noninferior to dulaglutide on cardiovascular events.[6][7] |

The three-year report is the one people mean when they say the drug has long-term data. It found substantial weight reduction sustained to week 176 and markedly fewer diabetes diagnoses than placebo, 1.3 percent against 13.3 percent, and its safety conclusion was a single sentence: no new safety signals were identified.[4] Read that sentence precisely. It says nothing new appeared over three years, not that nothing new exists at five.

A trial built to answer the outcome question in obesity is running. SURMOUNT-MMO enrolled 15,374 participants, is listed as active and no longer recruiting, and has a primary completion date of October 2027.[11] Until it reports, the morbidity and mortality question for people taking tirzepatide without diabetes has no trial answer at all. What the death data do show, and what they do not, is in [tirzepatide and longevity](https://glpwatchdog.org/research/tirzepatide-and-longevity).

## A warning is not a rate

This is the distinction that decides how worried to be, and almost nothing written about GLP-1 drugs preserves it. A warning in an approved label is a disclosure FDA required, based on a plausible association, an animal finding, or reports gathered after approval. A rate is the result of counting events among people who were randomized. The two look identical on a page of bullet points and mean very different things.

The table below reads the Zepbound label, because that is the presentation approved for weight reduction. Mounjaro, the same molecule approved for type 2 diabetes, carries the same set of warnings, with the retinopathy one written for patients who already have a history of diabetic retinopathy. Since August 2026 it also carries a cardiovascular indication that Zepbound does not.[2] If you are taking tirzepatide for diabetes, that is the label your prescription is written against.

*Each labeled long-term concern in the Zepbound prescribing information, and whether a counted number sits behind it.*

| Labeled concern | What the label rests it on | Is there a rate? |
| --- | --- | --- |
| Thyroid C-cell tumors, including medullary thyroid carcinoma | A 2-year rat study. The label states plainly that human relevance has not been determined.[1] | **No human rate.** The finding is in rats. |
| Acute pancreatitis | Cases seen in people on this drug and on GLP-1 receptor agonists generally. The warning section attaches no number to them.[1] | **Yes, elsewhere in the label, and it matches placebo.** Adjudicated acute pancreatitis was 0.2% on tirzepatide and 0.2% on placebo in the pooled weight trials.[1] |
| Acute gallbladder disease | An increased occurrence with tirzepatide and with GLP-1 receptor agonists, associated with weight reduction.[1] | **Yes, and it is small but real.** Cholecystitis 0.7% against 0.2%; cholelithiasis 1.1% against 1%; cholecystectomy 0.2% against none.[1] |
| Acute kidney injury from volume depletion | Postmarketing reports, some requiring hemodialysis, mostly in people who had lost fluid through nausea, vomiting or diarrhea.[1] | **No trial rate.** Postmarketing reports have no denominator. |
| Diabetic retinopathy complications | Temporary worsening has been reported when glucose control improves quickly. An August 2026 revision dropped the earlier list of retinopathy populations never studied.[1] | **No rate in this label.** It is a monitoring instruction for people with a retinopathy history. |
| Severe gastrointestinal reactions | Reported more often on drug than placebo in the pooled weight trials; not recommended in severe gastroparesis.[1] | **Yes.** 1.7%, 2.5% and 3.1% by dose, against 1% on placebo.[1] |

Read the pancreatitis row twice. Pancreatitis is the risk people fear most on these drugs, it carries a full warning section, and in the pooled weight-reduction trials the adjudicated rate on tirzepatide was the same as the rate on placebo. That does not make the warning wrong or removable. The warning is doing what a warning does, telling a clinician what to watch for; it is not evidence that the drug caused pancreatitis at a measurable rate in those trials.

## The boxed warning, read carefully

The strongest warning on the label is the one at the top, and it is entirely an animal finding.

In a two-year rat study, thyroid C-cell tumors rose with the size of the dose and with how long the animals were exposed, at exposures the label calls clinically relevant.[1] Whether the same thing happens in people has, in the label's own phrasing, not been determined.[1] Nothing stronger than that is claimed, and nothing weaker is permitted either: the warning sits in a black box at the top of the document.

Two things follow from it, and only two. The first is a hard contraindication for anyone carrying type 2 multiple endocrine neoplasia syndrome and for anyone whose own medical record or family record includes medullary thyroid carcinoma.[1] That is absolute, and it is a question to answer honestly with a prescriber before starting rather than a risk to weigh. The second is a short list of symptoms to watch for: a mass in the neck, difficulty swallowing, shortness of breath, persistent hoarseness.[1]

What does not follow is a screening plan. The label describes routine calcitonin testing and thyroid ultrasound as being of uncertain value for catching MTC early, and as carrying their own risk of setting off procedures nobody needed.[1] Anyone selling you a thyroid panel as GLP-1 safety monitoring is going past the label.

## What the cardiovascular trial does and does not cover

SURPASS-CVOT is the longest controlled safety experience with tirzepatide that exists. It randomized 13,299 adults who had type 2 diabetes alongside established atherosclerotic disease, assigning them either tirzepatide or dulaglutide (whose cardiovascular benefit was already established), and ran to a median treatment duration of 46.9 months.[6][7] Heart attack, stroke or cardiovascular death, the primary composite, struck 12.2 percent of the tirzepatide group and 13.1 percent of the dulaglutide group: noninferior, and not statistically superior.[6]

For a long-term side effect question, the value of that trial is the four years of blinded follow-up rather than the efficacy verdict. Adverse events were broadly similar between the two groups, with more gastrointestinal events on tirzepatide (42.5 percent against 35.9 percent in the post hoc analysis of the same population).[7] There is a ceiling on what it transfers to, though. Everyone in it had diabetes and established heart disease, and they were compared against another incretin drug rather than against nothing. Zepbound's approved indications are weight reduction and obstructive sleep apnea; the label carries no cardiovascular risk-reduction claim.[1]

Mounjaro's label now does. In August 2026 FDA gave it [a second indication](https://glpwatchdog.org/research/mounjaro-heart-protection-surpass-cvot): cutting major cardiovascular events, meaning cardiovascular death, heart attack or stroke, among high-risk adults who have type 2 diabetes. The clinical studies section behind it is SURPASS-CVOT. The same section states that superiority to dulaglutide was not established.[2] The indication rests on matching a comparator that already held a cardiovascular claim, not on beating placebo. It also stays inside the trial's population: diabetes and high cardiovascular risk.

## Muscle: the part that is measured, and the part that is not

Lean-mass loss is the long-term worry that has traveled furthest ahead of its evidence, so start with what was measured. A substudy of SURMOUNT-1 scanned 160 of the 2,539 participants by DXA at baseline and week 72. On tirzepatide, body weight fell 21.3 percent, fat mass 33.9 percent and lean mass 10.9 percent; on placebo the corresponding figures were 5.3, 8.2 and 2.6 percent.[8]

The ratio matters more than any single number. About 75 percent of what came off was fat and about 25 percent was lean tissue, and that split was about the same in the placebo group.[8] So the composition of the loss looked like weight loss, not like a specific effect of the drug on muscle. Losing a quarter of your lost weight as lean mass still matters, particularly if you are older, and it is a reason to raise resistance training and protein intake with a clinician. It is not evidence that tirzepatide dissolves muscle.

> **What that substudy could not tell you.** 160 people is a small fraction of 2,539, it was scanned at one time point, and DXA measures tissue mass rather than strength or physical function. So we know the composition of the weight lost over 72 weeks, but this study cannot tell us what happened to what those muscles could do.

## Stopping: the best-documented long-term effect there is

SURMOUNT-4 was built to answer exactly this. Participants took tirzepatide open-label for 36 weeks, at which point 670 of them were randomly assigned to stay on the drug or move to placebo for 52 more weeks. Between week 36 and week 88, weight changed by -5.5 percent in the group that continued and by +14.0 percent in the group that stopped.[5] Of those who continued, 89.5 percent still held at least 80 percent of their run-in weight loss at week 88, against 16.6 percent of those who stopped.[5] What stopping looks like in practice, including side effects and the half-life, is in [stopping tirzepatide: weight regain and side effects](https://glpwatchdog.org/research/stopping-tirzepatide-weight-regain).

The three-year trial adds a second angle. After 176 weeks of treatment and then 17 weeks with no drug at all, 2.4 percent of the tirzepatide participants had type 2 diabetes against 13.7 percent of the placebo participants. Some of the metabolic benefit survived the washout, even as weight began to come back.[4]

The practical reading is unglamorous: this behaves like ongoing therapy for a chronic condition, not like a course of something. That has consequences for supply, for cost, and for what happens when a program ends for reasons unconnected to anything you did. We walk through that situation in [what to do when a compounded GLP-1 program ends](https://glpwatchdog.org/research/compounded-glp1-going-away-what-to-do). If you are thinking of stopping because of cost, tell your prescriber first, and compare the dated figures on our [price tracker](https://glpwatchdog.org/price-tracker) rather than a seller's headline.

If it is ongoing therapy, how a program bills over years matters as much as the first month. [TMates](https://glpwatchdog.org/reviews/tmates) and [Collective](https://glpwatchdog.org/reviews/collective) charge the same at every dose of compounded tirzepatide, though Collective adds a required annual membership on top. [Queen RX](https://glpwatchdog.org/reviews/queen-rx) sells one-time three-month packs with no subscription, and [AVARA Rx](https://glpwatchdog.org/reviews/avara-rx) leaves each monthly refill for you to pay rather than billing it automatically.

Watch for the opposite model early, since most people climb the dose ladder over the first months. [Coby Health](https://glpwatchdog.org/reviews/coby-health) prices compounded tirzepatide by dose, so the monthly charge goes up with each step from the 2.5 mg start. [bmiMD](https://glpwatchdog.org/reviews/bmimd) takes the flat approach instead, charging $179 for a one-month plan of compounded tirzepatide at every dose.

Continuity of care counts for the same reason. [YOURx Health](https://glpwatchdog.org/reviews/yourx-health) runs care through MD Integrations with a physician video visit, and [MediRX](https://glpwatchdog.org/reviews/medirx) has OpenLoop Health’s clinicians prescribe. [Blue Sky MD](https://glpwatchdog.org/reviews/blue-sky-md) sells the medication only inside a full program with one-on-one coaching, and [Harbor](https://glpwatchdog.org/reviews/harbor) adds a registered dietitian after the medication phase ends, the stage the stopping trial above describes.

## Where the record simply stops

- **Beyond about three and a half years in obesity.** 176 weeks is the end of the published randomized road, and that report covers the prediabetes subgroup.[4]
- **Cancer risk in humans.** The boxed warning is a rat study. A three-and-a-half-year trial is not long enough to settle a question about tumors that take decades to appear, and no trial of this length could be.[1][4]
- **Outcomes in people without diabetes.** The cardiovascular evidence comes from a diabetes population with established heart disease. SURMOUNT-MMO does not complete until October 2027.[6][11]
- **Function, as opposed to tissue mass.** [The body-composition data](https://glpwatchdog.org/research/lists/top-glp1-muscle-preservation-studies) describe what was lost, not what changed about strength.[8]
- **Anything about compounded tirzepatide over years.** There is no trial of any compounded formulation, at any duration, which is a separate problem we take apart in [compounded tirzepatide side effects](https://glpwatchdog.org/research/compounded-tirzepatide-side-effects).

This is what a young drug's evidence base looks like, and a seller who answers a long-term safety question with more confidence than the trials support is telling you something about the seller. Which pharmacy stands behind a given program is recorded in our [pharmacy register](https://glpwatchdog.org/pharmacies), and the programs themselves sit on the [compounded tirzepatide board](https://glpwatchdog.org/best/compounded-tirzepatide).

## Frequently asked questions

### How long has tirzepatide been studied?

The longest published randomized treatment period in obesity is 176 weeks, from the three-year report of SURMOUNT-1, which followed the participants who had both obesity and prediabetes. In type 2 diabetes, SURPASS-CVOT ran to a median treatment duration of 46.9 months against an active comparator. The drug was first approved in the United States in May 2022 for diabetes and November 2023 for weight reduction, so the postmarketing record is shorter than the marketing suggests.

### Does tirzepatide cause thyroid cancer?

Nobody knows, and the label says so. A two-year rat study found thyroid C-cell tumors rising with both the size of the dose and the length of exposure, and the prescribing information records that the human relevance of that result has not been determined. What follows is a firm contraindication covering type 2 multiple endocrine neoplasia syndrome, and covering anyone whose own record or family record includes medullary thyroid carcinoma. The label is also skeptical of screening: calcitonin testing and thyroid ultrasound are both described as being of uncertain value for catching it early.

### Is pancreatitis a real long-term risk?

It carries a full warning section, and in the pooled weight-reduction trials the adjudicated rate was 0.2 percent on tirzepatide and 0.2 percent on placebo. Those two facts are both true and they answer different questions. The warning tells a clinician to watch for it; the rate says the trials did not measure an excess. The symptom the label names is abdominal pain that is severe or will not go away, which sometimes reaches through to the back. That is a reason to seek care rather than to weigh statistics.

### Will I lose muscle if I stay on it for years?

The measurement we have covers 72 weeks in a DXA substudy of 160 people. Lean mass fell 10.9 percent on tirzepatide against 2.6 percent on placebo, but roughly 75 percent of what came off was fat in both groups, so the composition looked like weight loss rather than a drug effect on muscle specifically. Nothing in that substudy measured strength, and nothing in it runs past 72 weeks. Resistance training and protein intake are worth raising with a clinician rather than settling from a chart.

### What happens if I stop after a long time on it?

In SURMOUNT-4, people who switched to placebo after 36 weeks of treatment regained 14.0 percent of body weight over the following 52 weeks, while those who continued lost a further 5.5 percent. Only 16.6 percent of the placebo group still held at least 80 percent of their earlier weight loss, against 89.5 percent of those who continued. Some metabolic benefit outlasted the drug in the three-year trial, where diabetes diagnoses stayed low through 17 weeks off treatment, while weight began to come back. Stopping belongs to you and a prescriber together, and it should not be decided by a supply problem.

### Do the long-term warnings apply to compounded tirzepatide too?

The molecule is the same, so the labeled warnings for the approved product describe the same pharmacology. What does not carry over is the evidence: no compounded formulation has been through any trial, at any duration, and a compounded vial may contain ingredients the approved product does not. Anyone extending a three-year safety record to a compounded preparation is borrowing a number that was never measured on it.

## References

1. Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information (boxed warning; sections 1, 5.2, 5.3, 5.4, 5.5, 5.8, 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
2. Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information (sections 1, 5, 14.6). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387(3):205-216. 2022. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
4. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 2025;392(10):958-971. 2025. PMID: 39536238. https://pubmed.ncbi.nlm.nih.gov/39536238/
5. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. 2024. PMID: 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/
6. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025;393(24):2409-2420. 2025. PMID: 41406444. https://pubmed.ncbi.nlm.nih.gov/41406444/
7. Nissen SE, Wolski K, D'Alessio D, et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol 2026;11(6):544-552. 2026. PMID: 41903177. https://pubmed.ncbi.nlm.nih.gov/41903177/
8. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025. 2025. PMID: 39996356. https://pubmed.ncbi.nlm.nih.gov/39996356/
9. U.S. Food and Drug Administration Drugs@FDA: MOUNJARO (tirzepatide), NDA 215866 — original approval May 13, 2022. FDA Drugs@FDA database. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
10. U.S. Food and Drug Administration Drugs@FDA: ZEPBOUND (tirzepatide), NDA 217806 — original approval November 8, 2023. FDA Drugs@FDA database. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
11. Eli Lilly and Company A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO), NCT05556512. ClinicalTrials.gov, U.S. National Library of Medicine. 2026. https://clinicaltrials.gov/study/NCT05556512

---

Cite as: GLP Watchdog, Ruth Calder, "Tirzepatide Long-Term Side Effects: Where the Evidence Stops", published 2026-08-14, updated 2026-11-07. https://glpwatchdog.org/research/tirzepatide-long-term-side-effects

Canonical HTML page: https://glpwatchdog.org/research/tirzepatide-long-term-side-effects

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
